MedImmune LLC
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 1987-01-01
- Employees
- 5K
- Market Cap
- -
- Website
- http://medimmune.com
Study of the Tumor Saturation and Biological Activity of MEDI-522 (Abergrin) in Patients With Advanced Malignant Melanoma
- First Posted Date
- 2005-05-25
- Last Posted Date
- 2012-03-14
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 18
- Registration Number
- NCT00111696
- Locations
- 🇺🇸
University Of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, United States
Study to Evaluate the Immune Responses of Trivalent Cold-Adapted Influenza Vaccine (CAIV-T) Compared With (TIV)
- First Posted Date
- 2005-05-24
- Last Posted Date
- 2008-07-24
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 52
- Registration Number
- NCT00111579
- Locations
- 🇺🇸
Alpine Pediatrics, Pleasant Grove, Utah, United States
🇺🇸Wee Care Pediatrics, Layton, Utah, United States
🇺🇸Families First Pediatrics, South Jordan, Utah, United States
Study to Evaluate MEDI-507 in Patients With CD2-Positive Lymphoma/Leukemia
- First Posted Date
- 2005-03-14
- Last Posted Date
- 2007-06-14
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 80
- Registration Number
- NCT00105313
- Locations
- 🇺🇸
USC/Norris Cancer Center, Los Angeles, California, United States
🇺🇸Yale Cancer Center, New Haven, Connecticut, United States
🇺🇸Georgetown University Medical Center, Lombardi Comprehensive Cancer Center, Washington, District of Columbia, United States
Study Evaluating the Addition of Amifostine (Ethyol®) to Idarubicin and Cytosine Arabinoside in Older Patients With Acute Myeloid Leukemia
- Conditions
- Interventions
- First Posted Date
- 2004-06-25
- Last Posted Date
- 2009-01-29
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 54
- Registration Number
- NCT00086099
- Locations
- 🇮🇱
Sheba Medical Center, Tel Hasomer, Israel
🇺🇸Cancer Care Center, New Albany, Indiana, United States
🇺🇸Wake Forest University School of Medicine, Winston-Salem, North Carolina, United States
Subcutaneous Amifostine (Ethyol®) in the Prevention of Radiochemotherapy-Induced Esophagitis and Pneumonitis in Patients With Unresectable Non-Small Cell Lung Cancer
- Conditions
- First Posted Date
- 2004-04-09
- Last Posted Date
- 2007-08-21
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 130
- Registration Number
- NCT00081315
- Locations
- 🇺🇸
St. Agnes Health Care, Baltimore, Maryland, United States
🇺🇸Long Island Jewish Medical Center, New Hyde Park, New York, United States
🇺🇸Center for Cancer & Blood Disorders, Bethesda, Maryland, United States
BL22 Immunotoxin In Treating Young Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Non-Hodgkin's Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2004-02-12
- Last Posted Date
- 2007-12-28
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 95
- Registration Number
- NCT00077493
- Locations
- 🇺🇸
Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office, Bethesda, Maryland, United States
BL22 Immunotoxin in Treating Patients Previously Treated With Cladribine for Hairy Cell Leukemia
- First Posted Date
- 2003-12-11
- Last Posted Date
- 2010-06-22
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 36
- Registration Number
- NCT00074048
- Locations
- 🇺🇸
Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office, Bethesda, Maryland, United States
MEDI-522 in the Treatment of Patients With Metastatic Androgen-Independent Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2003-11-17
- Last Posted Date
- 2008-01-15
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 150
- Registration Number
- NCT00072930
- Locations
- 🇺🇸
Raleigh Hematology Oncology Association, Raleigh, North Carolina, United States
🇺🇸Hubert H. Humphrey Cancer Center, Robbinsdale, Minnesota, United States
🇺🇸Clinical Research Services, Bismark, North Dakota, United States
Effects of MEDI-522 On Disease Activity and Progression of Joint Damage in Patients With Active Rheumatoid Arthritis Suboptimally Responding to Methotrexate
- First Posted Date
- 2003-09-17
- Last Posted Date
- 2007-11-27
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 300
- Registration Number
- NCT00069017
- Locations
- 🇺🇸
RIMA, St. Louis, Missouri, United States
🇨🇦Midtown Medical Center, Saskatoon, Saskatchewan, Canada
🇺🇸Thornton Hospital, La Jolla, California, United States
Evaluating The Antitumor Activity Of MEDI-522 With Or Without Dacarbazine In Patients With Metastatic Melanoma
- Conditions
- Interventions
- First Posted Date
- 2003-08-07
- Last Posted Date
- 2008-01-15
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 110
- Registration Number
- NCT00066196
- Locations
- 🇺🇸
Mayo Clinic Arizona, Scottsdale, Arizona, United States
🇺🇸Johns Hopkins University - SKCC at Johns Hopkins, Lutherville, Maryland, United States
🇺🇸Vanderbilt University Medical Center, Nashville, Tennessee, United States